Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

78.62EUR
31 Jul 2014
Price Change (% chg)

€1.73 (+2.25%)
Prev Close
€76.89
Open
€79.48
Day's High
€80.00
Day's Low
€78.60
Volume
6,701,388
Avg. Vol
2,279,026
52-wk High
€80.74
52-wk Low
€68.29

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.55
Market Cap (Mil.): €101,697.20
Shares Outstanding (Mil.): 1,322.62
Dividend: 2.80
Yield (%): 3.64

Financials

  SASY.PA Industry Sector
P/E (TTM): 27.16 35.82 36.29
EPS (TTM): 2.83 -- --
ROI: -- 18.85 18.13
ROE: -- 19.57 18.95
Search Stocks

Sanofi sees first dengue vaccine filings in first quarter of 2015

PARIS - Sanofi expects to submit regulatory applications for the world's first dengue vaccine in the first quarter of 2015 and the French drugmaker could start selling the first batches at the end of that year, CEO Chris Viehbacher said on Thursday.

31 Jul 2014

Sanofi sees first dengue vaccine filings in Q1 2015

PARIS, July 31 - Sanofi expects to submit regulatory applications for the world's first dengue vaccine in the first quarter of 2015 and the French drugmaker could start selling the first batches at the end of that year, CEO Chris Viehbacher said on Thursday.

31 Jul 2014

Sanofi lifts profit forecast as second quarter beats expectations

PARIS - French drugmaker Sanofi raised its full-year profit forecast on Thursday as it posted stronger than expected quarterly earnings, driven by its rare disease and diabetes businesses and higher sales in emerging markets.

31 Jul 2014

UPDATE 2-Sanofi lifts profit forecast as Q2 beats expectations

* Aims for 6-8 pct rise in 2014 business EPS up from 4-7 pct

31 Jul 2014

Adidas pulls European stocks lower

* FTSEurofirst 300 down 0.5 pct, Euro STOXX 50 down 0.6 pct

31 Jul 2014

Europe shares steady at open; Sanofi rises after results

PARIS, July 31 - European shares were steady in early trade on Thursday as investors combed through a batch of corporate results from blue-chips such as Sanofi, Anheuser-Busch InBev and Royal Dutch Shell.

31 Jul 2014

Sanofi lifts 2014 guidance after second quarter earnings beat expectations

PARIS - French drugmaker Sanofi raised its full-year guidance on Thursday after it posted stronger than expected quarterly earnings, driven by its rare disease business and higher sales in emerging markets.

31 Jul 2014

BRIEF-Sanofi CEO comments Q2 results on conference call

July 31 - Sanofi SA Chief Executive Chris Viehbacher tells reporters: * Expects vaccines business to return to double-digit growth in H2 * "Could imagine" U.S. launch of cholesterol drug alirocumab in H2 2015,

31 Jul 2014

Sanofi lifts 2014 guidance after Q2 earnings beat expectations

PARIS, July 31 - French drugmaker Sanofi raised its full-year guidance on Thursday after it posted stronger than expected quarterly earnings, driven by its rare disease business and higher sales in emerging markets.

31 Jul 2014

Sanofi, Regeneron cholesterol drug may cut heart risk, trial hints

NEW YORK/PARIS - A new drug being developed by Sanofi SA and Regeneron Pharmaceuticals Inc significantly cut cholesterol in nine late-stage clinical trials, the companies said on Wednesday, and provided the first glimpse of its potential to prevent heart attacks and strokes.

30 Jul 2014

Earnings vs. Estimates

Search Stocks